COST

949.4

+0.92%↑

PG

156.95

+0.54%↑

KO

68.81

+0.01%↑

PM

164.14

-1.83%↓

PEP

147.73

+0.56%↑

COST

949.4

+0.92%↑

PG

156.95

+0.54%↑

KO

68.81

+0.01%↑

PM

164.14

-1.83%↓

PEP

147.73

+0.56%↑

COST

949.4

+0.92%↑

PG

156.95

+0.54%↑

KO

68.81

+0.01%↑

PM

164.14

-1.83%↓

PEP

147.73

+0.56%↑

COST

949.4

+0.92%↑

PG

156.95

+0.54%↑

KO

68.81

+0.01%↑

PM

164.14

-1.83%↓

PEP

147.73

+0.56%↑

COST

949.4

+0.92%↑

PG

156.95

+0.54%↑

KO

68.81

+0.01%↑

PM

164.14

-1.83%↓

PEP

147.73

+0.56%↑

Search

Hims & Hers Health Inc

Fechado

SetorConsumo Básico

44.03 -3

Visão Geral

Variação de preço das ações

24h

Atual

Mín

44.01

Máximo

45.88

Indicadores-chave

By Trading Economics

Rendimento

-7M

43M

Vendas

-41M

545M

P/E

Médio do Setor

54.418

27.327

Margem de lucro

7.801

Funcionários

1,637

EBITDA

-29M

37M

Recomendações

By TipRanks

Recomendações

Neutro

Previsão para 12 meses

+11.44% upside

Dividendos

By Dow Jones

Próximos Ganhos

3 de nov. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

-4.5B

9.7B

Abertura anterior

47.03

Fecho anterior

44.03

Sentimento de Notícias

By Acuity

50%

50%

58 / 150 Ranking em Consumer defensive

Pontuação Técnica

By Trading Central

Confiança

Bullish Evidence

Hims & Hers Health Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

5 de ago. de 2025, 00:05 UTC

Ações em Alta

Stocks to Watch: Palantir Technologies, Hims & Hers Health, Vertex Pharmaceuticals, Kyndryl

29 de abr. de 2025, 12:54 UTC

Grandes Movimentos do Mercado

Hims & Hers Rallies After Novo Nordisk Deal on Wegovy

4 de abr. de 2025, 22:38 UTC

Ações em Alta

Stocks to Watch: Eli Lilly, Novo Nordisk, Hims & Hers, Maxeon Solar Technologies

1 de abr. de 2025, 23:15 UTC

Grandes Movimentos do Mercado

Hims & Hers Adds Eli Lilly's Zepbound in Expansion of Weight-Loss Offerings -- 2nd Update

25 de fev. de 2025, 15:33 UTC

Grandes Movimentos do Mercado

Novo Nordisk Shares Rise as Hims & Hers to Stop Mimicking Weight-Loss Drugs

18 de nov. de 2024, 19:07 UTC

Grandes Movimentos do Mercado

Hims & Hers Stock Climbs After Former Regulator Autor Joins Board

14 de out. de 2024, 15:02 UTC

Grandes Movimentos do Mercado

Hims & Hers Health Shares Jump After FDA Set to Reconsider Limits on Knockoff Weight-Loss Drugs

5 de ago. de 2025, 20:44 UTC

Ganhos

These Stocks Moved the Most Today: Palantir, Vertex, Hims & Hers, Coinbase, BP, and More -- Barrons.com

5 de ago. de 2025, 18:17 UTC

Ganhos

These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, Coinbase, BP, and More -- Barrons.com

5 de ago. de 2025, 17:26 UTC

Ganhos
Aquisições, Fusões, Aquisições de Empresas

Hims & Hers Had a Tough Quarter. Weight-Loss Drugs Are Only One Problem. -- Barrons.com

5 de ago. de 2025, 15:25 UTC

Ganhos

Correction to These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, Caterpillar, BP, and More -- Barrons.com

5 de ago. de 2025, 11:27 UTC

Ganhos

Update: These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, AMD, BP, and More -- Barrons.com

5 de ago. de 2025, 10:55 UTC

Ganhos

Update: These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, AMD, BP, and More -- Barrons.com

5 de ago. de 2025, 10:36 UTC

Ganhos

Update: These Stocks Are Moving the Most Today: Palantir, Vertex, Hims & Hers, AMD, BP, and More -- Barrons.com

29 de jul. de 2025, 16:55 UTC

Ganhos

The Obesity Bubble Has Finally Burst. Novo Nordisk Shares Drop 21%. -- Barrons.com

24 de jun. de 2025, 10:26 UTC

Conversa de Mercado

Novo Nordisk Sends Clear Message on Copycat Drugs -- Market Talk

3 de jun. de 2025, 15:03 UTC

Aquisições, Fusões, Aquisições de Empresas

Hims & Hers Seeks Growth in Europe as Weight-Loss Business Shifts -- Barrons.com

7 de mai. de 2025, 13:56 UTC

Ganhos

Novo Nordisk Stock Jumps After Earnings. Compounding Market's Growth Took it By Surprise -- Barrons.com

6 de mai. de 2025, 14:24 UTC

Ganhos

Hims & Hers Stock Is Higher After Earnings. The Sales Outlook Looks Low. -- Barrons.com

30 de abr. de 2025, 09:30 UTC

Principais Notícias

Why New Wegovy Deals Won't Restore Novo's Obesity Lead -- Heard on the Street -- WSJ

2 de abr. de 2025, 16:53 UTC

Principais Notícias

Hims & Hers Zepbound Offering Won't Bring Needed Sales Boom -- Analysis

19 de mar. de 2025, 15:54 UTC

Principais Notícias

Sale of Ozempic Knockoffs Are Supposed to End Soon. Telehealth Companies Aren't Happy. -- WSJ

21 de fev. de 2025, 23:20 UTC

Ganhos

These Stocks Moved the Most Today: UnitedHealth, Alibaba, Rivian, Celsius, Booking, Block, Akamai, Hims & Hers, and More -- Barrons.com

10 de fev. de 2025, 12:00 UTC

Principais Notícias

Hims Super Bowl Ad Spotlights Weight-Loss Drug Copycats as Clock Ticks on Their Business -- Heard on the Street -- WSJ

19 de dez. de 2024, 17:16 UTC

Principais Notícias

FDA Says Shortage of Eli Lilly's Zepbound is Over, But Gives Compounders a Grace Period -- Barrons.com

19 de dez. de 2024, 15:14 UTC

Principais Notícias

Eli Lilly's Zepbound Shortage Is Officially Over, FDA Says -- Barrons.com

19 de dez. de 2024, 15:02 UTC

Principais Notícias

The Zepbound Shortage Is Officially Over, FDA Says -- Barrons.com

16 de dez. de 2024, 13:47 UTC

Principais Notícias

The Weight-Loss Drug Market Is Heading for a Reckoning This Week -- Barrons.com

16 de dez. de 2024, 07:00 UTC

Principais Notícias

The Weight-Loss Drug Market Is Heading for a Reckoning This Week. What to Expect. -- Barrons.com

3 de out. de 2024, 14:45 UTC

Principais Notícias

Eli Lilly's Weight-Loss Drugs Are No Longer in Short Supply. Bad News for Hims & Hers. -- Barrons.com

Comparação entre Pares

Variação de preço

Hims & Hers Health Inc Previsão

Preço-alvo

By TipRanks

11.44% parte superior

Previsão para 12 meses

Média 47.91 USD  11.44%

Máximo 85 USD

Mínimo 28 USD

Com base em 12 analistas de Wall Street que oferecem metas de preço de 12 meses para Hims & Hers Health Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Neutro

12 ratings

2

Comprar

8

Manter

2

Vender

Pontuação Técnica

By Trading Central

36.685 / 52.35Suporte e Resistência

Curto Prazo

Bullish Evidence

Médio Prazo

Bullish Evidence

Longo Prazo

Bullish Evidence

Sentimento

By Acuity

58 / 150 Ranking em Consumo Básico

Sentimento de Notícias

Neutral

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Hims & Hers Health Inc

Hims & Hers Health, Inc. operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers. It also provides prescription medication on a recurring basis and ongoing care from healthcare providers; and over-the-counter drug and device products, cosmetics, and supplement products primarily focusing on general wellness, sexual health and wellness, skincare, and hair care. In addition, the company's curated non-prescription products include melatonin and biotin in the wellness specialty category; moisturizers, creams, sunscreen, serum, face oil, and face wash in the skincare specialty; condoms, climax delay spray and wipes, vibrators, and lubricants in the sexual health and wellness specialty; and shampoos, conditioners, scalp scrubs, and topical treatments, such as minoxidil in the hair care specialty category. Further, it offers medical consultation and post-consultation support services, as well as health and wellness products through wholesale partners. Hims & Hers Health, Inc. is based in San Francisco, California.